PDE-4 Inhibitor Roflumilast and Polycystic Ovary Syndrome

Summary

The purpose of this study was to determine whether combined treatment with phosphodiesterase-4 (PDE-4) inhibitor roflumilast and metformin is more effective than metformin as monotherapy in the treatment of obese women with polycystic ovary syndrome (PCOS) who had been previously poor responders regarding weight reduction on metformin monotherapy. The investigators anticipated greater changes in body weight in patients on combined treatment than in those on monotherapy with metformin.

Timeline

Start

2013-09

Primary completion

2013-12

Completion

2014-01

Drugs

Indications